eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | scleroderma |
| Comorbidity | C0020538|hypertension |
| Sentences | 11 |
| PubMedID- 24351825 | Finally, increased adma serum levels are involved in the development of pulmonary vascular disease in scleroderma subjects with pulmonary artery hypertension (pah) [38]. |
| PubMedID- 21548946 | Furthermore, it has been shown that gdf-15 serum levels are increased in scleroderma patients with pulmonary hypertension and gdf-15 protein was predominantly located in monocytes infiltrating the lung tissue [18]. |
| PubMedID- 20862337 | The prevalence of pulmonary hypertension associated with scleroderma ranged from 4.9% to 38% as written in the accp guidelines. |
| PubMedID- 25145365 | Screening for pulmonary arterial hypertension in patients with scleroderma--a new zealand perspective. |
| PubMedID- 23042670 | Methods: we used data from 179 patients enrolled in the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry with pre-ph (defined by criteria on pulmonary function tests and/or echocardiogram) or definite ph with mean pulmonary artery pressure >/=25 mm hg by right-sided heart catheterization within 6 months of enrollment. |
| PubMedID- 21597395 | Objective: to detect coronary artery disease in asymptomatic patients with systemic lupus erythematosus and scleroderma associated with pulmonary hypertension, and to determine whether it is focal or diffuse ischemia. |
| PubMedID- 22215445 | Pulmonary arterial hypertension associated with scleroderma (sscpah) is a debilitating, highly lethal condition that responds to an array of therapies. |
| PubMedID- 20335527 | The presence of the hla-b35 allele has emerged as an important risk factor for the development of isolated pulmonary hypertension in patients with scleroderma, however the mechanisms underlying this association have not been fully elucidated. |
| PubMedID- 21844142 | Pulmonary hypertension assessment and recognition of outcomes in scleroderma (pharos): baseline characteristics and description of study population. |
| PubMedID- 25596924 | According to data from the north american pharos (pulmonary hypertension assessment and recognition of outcomes in scleroderma) study, who groups 2 and 3 ph account for 10% and 21%, respectively, of all types of ph in patients with ssc [26]. |
| PubMedID- 23983198 | Methods: the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry is a prospective registry of ssc patients at high risk for pah or with definite pulmonary hypertension diagnosed by right-sided heart catheterization within 6 months of enrollment. |
Page: 1